Drug intelligence / Profile preview

XLNT-1

Development stage: Preclinical
Lead developer: NAMI
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
Administration: Intraperitoneal

Overview

XLNT-1 is a targeted radiopharmaceutical being developed by NAMI Therapeutics for the treatment of advanced ovarian cancer and peritoneal metastases. It utilizes a nanoparticle-based delivery system to transport the radioactive isotope holmium-166 (Ho-166) directly to metastatic tumors within the peritoneal cavity. The therapy is designed for intraperitoneal administration, allowing the nanocarriers to remain confined to the abdominal space, thereby maximizing the radiation dose to cancer cells while minimizing systemic exposure and sparing healthy tissues. XLNT-1 is currently in the IND-enabling preclinical stage of development.

Targets

DNA

Beyond the preview

Go deeper on XLNT-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XLNT-1.

Explore the full profile